CA-AIRSPACE
Airspace today announced it has been granted a U.S. patent for its optimized logistics management system as of March 2. The patent covers the system, method, and computer programming of the logistical and graphical presentation of the most optimal path for transporting goods from a pickup location to a destination location at lowest transit cost and minimal risk.
Airspace leverages its patented technology and world-class team to provide certainty in the time-critical logistics space through unrivaled speed and shipment transparency . The routing operation is arguably the most important step in the logistical transportation process because the optimal route saves both money and time, while enabling customers to monitor progress along the route provides transparency.
“This technology is a game-changer for the supply chain and logistics industry,” said Ryan Rusnak , co-founder and CTO at Airspace.
Airspace’s technology calculates the best routes in less than a second instead of the typical 30 minutes or more that are standard in the time-critical shipping industry. The router generates a time and space expectation of where each order should be at any given time, which is checked via distributed sensors. Even if an expected flight is canceled, the technology immediately establishes a new plan and tracks it. Airspace provides automated notifications in real time to the customer instead of having to wait for personal contact calls, generating leading indicators rather than lagging ones.
“Our transparency with this process creates trust and confidence for both shippers and receivers,” said Rusnak. “We believe we are setting a new standard for the logistics industry.”
Logistical challenges are difficult because most shipments don’t start at an airport; they start at an arbitrary place such as a lab, warehouse, hospital, and so on. Airspace’s technology takes into consideration ground travel time as well, allowing for traffic to and from nearby airports to the final destination. This technology can provide the difference between life and death, for example, in the case of organs for transplant.
“If you choose a route that doesn’t give the driver enough time, you set the shipment up for failure. Create a route that is too conservative, and you risk losing the last flight that gets the package there when it’s needed,” said Nick Bulcao , co-founder and CEO of Airspace. “This is the extremely difficult optimization challenge that only Airspace can solve today, using our proprietary software and artificial intelligence. We are extremely proud of our inventors and pleased that our technology can make a real difference.”
Airspace, which recently closed its Series C funding round , is positioned to provide the best customer experience for clients while relentlessly analyzing data to address ongoing needs. It continues to grow, focused on making international expansion as seamless as possible by blending operations and R&D for the benefit of the industry.
About Airspace
Airspace, founded in 2016, has grown to be a leading global delivery network for time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through its people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints, Airspace surfaces more information than any other provider, increasing trust and transparency of the supply chain. To learn more, visit www.airspace.com . Follow Airspace: Twitter , Facebook , Instagram and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005325/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 01:00:00 CET | Press release
Stakeholder base expands with participation from an individual-investor-oriented fund, alongside corporate and individual investors, bringing Total Funding to USD 38M Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helic
Andersen Consulting udvider sin tilstedeværelse gennem samarbejde med Hilal Technology4.12.2025 23:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Hilal Technology for at styrke sine kompetencer inden for digital infrastruktur, cybersikkerhed og AI. Med tilstedeværelse i Bahrain, Saudi-Arabien, De Forenede Arabiske Emirater, Oman og Indien leverer Hilal Technology et komplet spektrum af digital infrastruktur og managed services inden for cloudcomputing, cybersikkerhed, enterprise ai og systemintegration. Deres ydelser omfatter cloudtjenester, sikkerheds- og netværksdrift, implementering af ERP og applikationer samt udvikling af generative ai-kapaciteter. Med et team på mere end 250 fagfolk servicerer firmaet en bred vifte af brancher, herunder den finansielle sektor, olie og gas, logistik og den offentlige sektor. "Transformation er mere end systemer; det handler om parathed, tillid og løbende samarbejde," udtaler Roshan George, direktør for Hilal Technology. "Vi er begejstrede for at samarbejde med Andersen Consulting og levere skalerbare løsninger, der matcher tempoet i den dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
